Short-term quazepam treatment of insomnia in geriatric patients

The efficacy and safety of 15 mg quazepam was compared with placebo in 57 geriatric outpatients with insomnia. The study was double-blind, with treatments randomly assigned to patients. Placebo was taken by all patients for the first 3 nights followed by either placebo or quazepam for 5 nights. Post...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 3(1982), 4 vom: 01., Seite 278-82
1. Verfasser: Caldwell, J R (VerfasserIn)
Format: Aufsatz
Sprache:English
Veröffentlicht: 1982
Zugriff auf das übergeordnete Werk:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
Schlagworte:Clinical Trial Journal Article Randomized Controlled Trial Anti-Anxiety Agents Benzodiazepines 12794-10-4 quazepam JF8V0828ZI
LEADER 01000caa a22002652c 4500
001 NLM061058815
003 DE-627
005 20250128061831.0
007 tu
008 231221s1982 xx ||||| 00| ||eng c
028 5 2 |a pubmed25n0204.xml 
035 |a (DE-627)NLM061058815 
035 |a (NLM)6128741 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Caldwell, J R  |e verfasserin  |4 aut 
245 1 0 |a Short-term quazepam treatment of insomnia in geriatric patients 
264 1 |c 1982 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 07.01.1983 
500 |a Date Revised 16.11.2017 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a The efficacy and safety of 15 mg quazepam was compared with placebo in 57 geriatric outpatients with insomnia. The study was double-blind, with treatments randomly assigned to patients. Placebo was taken by all patients for the first 3 nights followed by either placebo or quazepam for 5 nights. Post-sleep questionnaires were completed each day and the physician and patients rated the treatment at the end of the study. Quazepam was significantly better than placebo on all measures of efficacy. Indices of sleep quantity and quality showed that 15 mg quazepam produced significantly greater improvement in sleep than placebo on the first night of treatment and for the treatment period as a whole. There were no reports of unexpected or serious adverse experiences, and quazepam did not cause ataxia or impairment of motor co-ordination in any patient 
650 4 |a Clinical Trial 
650 4 |a Journal Article 
650 4 |a Randomized Controlled Trial 
650 7 |a Anti-Anxiety Agents  |2 NLM 
650 7 |a Benzodiazepines  |2 NLM 
650 7 |a 12794-10-4  |2 NLM 
650 7 |a quazepam  |2 NLM 
650 7 |a JF8V0828ZI  |2 NLM 
773 0 8 |i Enthalten in  |t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)  |d 1995  |g 3(1982), 4 vom: 01., Seite 278-82  |w (DE-627)NLM023961570 
773 1 8 |g volume:3  |g year:1982  |g number:4  |g day:01  |g pages:278-82 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_121 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 3  |j 1982  |e 4  |b 01  |h 278-82